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BTV-16 in Europe, an inactivated vaccine was produced from the reference field isolate 18 of bluetongue virus serotype 16. One group of six sheep was vaccinated subcutaneously 19 with the inactivated vaccine twice, on days 0 and 28, whereas a second group of 8 20 sheep was inoculated with saline solution and used as mock-vaccinated control 21 animals. Seventy eight days after the first vaccination, all sheep were inoculated 22 subcutaneously with a suspension containing 10 6.3 TCID 50 of a virulent reference BTV-23 16 isolate. Apart from a transient inflammatory reaction at the injection site, no adverse 24 effects were reported following vaccination. All vaccinated animals developed high titres 25 (7.3-9.3 Log 2 (ED50%/50µl)) of virus-specific neutralizing antibodies and were resistant There is an urgent need for a safe and efficacious vaccine which could be used in the 63 BTV vaccination campaign and that is capable of preventing the spread of BTV-16 in 64
Ita ly. In this study a BTV-16 inactivated vaccine was developed from the BTV-16 65 reference serotype and its safety and efficacy was evaluated in sheep which is the 66 species most susceptible to BTV. 67
Materials and Methods 68

Cells and Virus 69
Baby hamster kidney cells (BHK 21 , C13) were maintained in minimal essential medium 70 containing Earle's salts, L-glutamine and NAHCO 3 (EMEM) and supplemented with 71 nystatin, colistin and neomycin sulphate, and 10% foetal calf serum (FCS). The BTV-16 72 reference strain, obtained from the Virology Department of the Onderstepoort Veterinary 73
Institute, OIE Reference Laboratory for Bluetongue, Onderstepoort, South Africa, was 74 used as seed virus. 75
The seed virus was checked for the presence of contaminating bacteria, viruses, fungi 77 and mycoplasmas (European Pharmacopoeia, 2001). Its identity was confirmed by 78 serum neutralisation test. BHK 21 confluent monolayers in 175 cm 2 culture flasks were 79 used for virus amplification. When 80% of the monolayers showed CPE, the viral 80 suspension was harvested, centrifuged at 203 g for 10 min at 4°C, the supernatant 81 collected, dispensed in 1ml aliquots and stored at -80°C. The virus stock was checked 82 for purity, infectivity titre and identity. For the preparation of a batch of experimental 83 vaccine, BTV-16 at the third passage level was used to infect BHK 21 monolayers in 850 84 cm 2 roller bottles. The viral suspension (VS) was aseptically collected and clarified by 85 centrifugation at 9000 RPM (centrifuge Heraeus mod. Stratos 76000083) in continuous 86 flow (rotor Heraeus Titanium 3049) and tested for purity, infectivity titre and protein 87 concentration (BCATM Protein Assay Reagent Kit, Pierce, Rockford, IL). After passing 88 the tests, the suspension was purified and ten fold concentrated through a 300kD 89 molecular cut cassette membrane. During the purification-concentration phase, the VS 90 was kept on ice. The final product was again checked for purity (European 91
Pharmacopoeia, 2001), virus identity and infectivity titre. For inactivation, Tris-92
Hydroxymethyl-Amino methane (Tris) 1M pH 8.0 was added to the VS and stirred for 10 93 min at room temperature. Beta-propiolactone diluted in PBS pH 7.4 was subsequently 94 added to the VS to have a final dilution of the inactivant equal to 0.2% (v/v) (Parker et 95 al., 1975) . The suspension was stirred for 3 hours at 37 °C and then for 18 hours at 5°C. 96
The inactivated VS was subsequently checked in vitro for inactivation as follows. Three 97 175 cm² tissue culture flasks containing confluent monolayers of BHK21 cells were each 98 inoculated with 10 ml of inactivated VS. Three passages were carried out. If no CPE was 99 observed at the end of the third passage, the cells were scraped, fixed onto a slide and 100 
Safety tests 109
Two guinea pigs weighing 350g were injected subcutaneously with 2 ml doses each and 110 5 mice weighing 18 g with 0.5 ml each. The animals were monitored 7 days for any 111 clinical signs or local reaction at the injection site. 112
Efficacy test 113
Fourteen adult local cross bred sheep which tested negative for BTV-antibodies by 114 competitive enzyme linked immunosorbent assay (c-ELISA) were selected and housed 115 in insect-proof isolation facilities throughout these studies. 116
Six sheep were each inoculated subcutaneously with 2 ml of inactivated vaccine and 117 revaccinated 28 days later with the same dose. Similarly on the same days, the 118 remaining 8 sheep were inoculated subcutaneously with 2 ml of saline solution and used 119 as mock-vaccinated control animals. Rectal temperatures and injection sites of all 120 animals were monitored daily for 14 days. Blood samples were collected by jugular 121 puncture from each animals once a week from the day of vaccination and for the 122 following 8 weeks. Sera were separated, tested by c-ELISA and titrated for antibodies 123 against BTV-2, BTV-4, BTV-9 and BTV-16 by virus neutralisation (VN). 124 subcutaneous injection of 1 ml of viral suspension containing 10 6,3 TCDI 50 of BTV 126 serotype 16 reference isolate. Rectal temperature and clinical signs were recorded daily 127 for 14 days. Ethylene-diaminetetra-acetic acid (EDTA) blood samples were taken from 128 all animals three times a week for two months and tested for viraemia. An additional 129 serum sample was taken 60 days after challenge to determine the presence of BTV 130 specific antibodies using the c-ELISA and VN test. 131
The c-ELISA kit manufactured by IZSAM (Lelli et al., 2003) was used to test the sheep 132 sera according to the method described by the manufacturer. The neutralising titre was 133 determined as described by Savini et al. (2005) . EDTA blood samples were screened 134
for the presence of BTV and if virus was detected, the virus titre was determined for 135 each isolated virus as described previously (Savini et al., 2004) . Virus typing assay was 136 also employed to verify the serotype (Savini et al., 2004) . 137
Statistical analysis 138
Statistical significance of the tests was based on p values equal or lower than 0.05. 139
Differences between the viraemic titres of the vaccinated and unvaccinated groups of 140
sheep after challenge were analysed using the non parametric Mann-W hitney test for 141 independent groups (Siegel and Castellan, 1988) . For the daily rectal temperatures, the 142 mean values at the day of challenge were calculated for the vaccinated and 143 unvaccinated group and the statistical analysis was performed on the variations of the 144 daily temperature values from the group mean value at time 0. Statistical differences 145 between the variations were also determined using the Mann-W hitney test. 146
Results 147
Control of materials 148
Pharmacopoeia guidelines; controls for culture purity were found to be satisfactory. The 150 virus proved to be BTV-16 with a titre of 10 7,3 TCID/ml. 151
Vaccine production and in process control 152
Forty eight hours after infection, the BHK21 monolayer in the 175 cm 2 roller bottles 153 showed 100% CPE. The viral suspension had a titre of 10 7.6 TCID 50 /ml and a protein 154 concentration equal to 1.631 mg/ml. Viral identity, sterility and absence of viral 155 contaminants were confirmed. Following the purification process, the BTV titre of the VS 156 was 10 7.7 TCID 50 /ml while the protein concentration was 2.577 mg/ml. The final product 157 was also found to be free of contaminants. The in vitro inactivation test was satisfactory 158 and no fever or adverse effects either in mice or guinea pigs were observed after 159 inoculation. (ED50%/50µl)) and dropping to 5.64 just before challenge (Fig. 1) . 171
Protection of sheep immunized with BTV-16 inactivated vaccine temperature remained normal. Conversely, seven of the 8 unvaccinated control animals 174 developed 2 to 6 days of hyperthermia within the first week of challenge. The increase 175 was significantly higher (p < 0.05) on days 5, 6 and 7 post challenge (pc) as compared 176 to the animals in the vaccinated group. Average evolution of rectal temperatures of the 177 groups are presented in Fig. 2 . An unvaccinated anima l also showed nasal discharge 178 on days 4 and 5 pc. BTV-16 virus was isolated in the blood of all unvaccinated control 179 animals from day 3 to day 35 pc, with peak titres observed on day 5 pc (Fig. 3) . In none 180 of the vaccinated animals was BTV ever detected. They were significantly protected 181 from viraemia up to day 21 pc as compared to control animals. No animal developed 182 BTV-2, 4 and 9 antibody titres. On day 60 pc, the BTV-16 challenged group showed high 183 homologous neutralising antibody titres. Eaton, 1996; 197 in field trials (Roy et al. 1990 (Roy et al. , 1992 (Roy et al. , 1994 Roy, 2004) and difficulties with commercial 199 production, cost, and long-term stability, make them ineligible for field use (Savini et al., 200 2006 , 1996) . 239
In conclusion, although further studies involving larger number of animals and different 240 species will be required, this investigation has shown that a two-dose schedule 241
Montanide-adjuvanted BTV-16 inactivated vaccine appears to safely and effectively 242 induce protective immunity in sheep. It possesses the attributes which would make it 243 suitable for a BTV vaccination campaign, is preferable to the existing MLV BTV-16 244 vaccines and ideal for use in BTV-free countries where emergency ring vaccination may 245 be necessary. However, it is important to note that an effective vaccine although crucial 246 is only one factor in a multi-faceted control programme. To achieve complete control of 247 
